Skip to search formSkip to main contentSkip to account menu

canakinumab 180 MG Injection [Ilaris]

Known as: CANAKINUMAB 150 mg in 1 mL SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Ilaris], ILARIS 180 MG Injection 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Cryopyrin-Associated Periodic Syndrome (CAPS) is combination of different autoinflammatory hereditary disorders with same genetic… 
Review
2013
Review
2013
Background There have been few published comparisons of various treatment options for acute gout flares that incorporate costs… 
2013
2013
Background Canakinumab (CAN, Ilaris®), a fully human anti-IL-1β monoclonal antibody, selectively inhibits IL-1β and has been…